Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

2.

How can molecular abnormalities influence our clinical approach.

Wei W, Giulia F, Luffer S, Kumar R, Wu B, Tavallai M, Bekele RT, Birrer MJ.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii16-viii24. doi: 10.1093/annonc/mdx447. Review.

PMID:
29232470
3.

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.

Booth L, Albers T, Roberts JL, Tavallai M, Poklepovic A, Lebedyeva IO, Dent P.

Oncotarget. 2016 Jun 28;7(26):40398-40417. doi: 10.18632/oncotarget.9752.

4.

Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.

Tavallai M, Booth L, Roberts JL, Poklepovic A, Dent P.

Front Oncol. 2016 Jun 13;6:142. doi: 10.3389/fonc.2016.00142. eCollection 2016.

5.

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.

Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, Koromilas AE, Boone DL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 26;7(17):23608-32. doi: 10.18632/oncotarget.8281.

6.

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.

Tavallai M, Booth L, Roberts JL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 5;7(14):17290-300. doi: 10.18632/oncotarget.8039.

7.

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.

Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 12;7(15):19620-30. doi: 10.18632/oncotarget.7746.

8.

Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.

Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, Ecroyd H, Lebedyeva IO, Dent P.

Oncotarget. 2016 Mar 15;7(11):12975-96. doi: 10.18632/oncotarget.7349.

9.

GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.

Roberts JL, Tavallai M, Nourbakhsh A, Fidanza A, Cruz-Luna T, Smith E, Siembida P, Plamondon P, Cycon KA, Doern CD, Booth L, Dent P.

J Cell Physiol. 2015 Oct;230(10):2552-78. doi: 10.1002/jcp.25014.

10.

Differential regulation of autophagy and cell viability by ceramide species.

Cruickshanks N, Roberts JL, Bareford MD, Tavallai M, Poklepovic A, Booth L, Spiegel S, Dent P.

Cancer Biol Ther. 2015;16(5):733-42. doi: 10.1080/15384047.2015.1026509.

11.

OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies.

Booth L, Roberts JL, Tavallai M, Nourbakhsh A, Chuckalovcak J, Carter J, Poklepovic A, Dent P.

J Cell Physiol. 2015 Aug;230(8):1982-98. doi: 10.1002/jcp.24977.

12.

Nexavar/Stivarga and viagra interact to kill tumor cells.

Tavallai M, Hamed HA, Roberts JL, Cruickshanks N, Chuckalovcak J, Poklepovic A, Booth L, Dent P.

J Cell Physiol. 2015 Sep;230(9):2281-98. doi: 10.1002/jcp.24961.

Supplemental Content

Loading ...
Support Center